Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7630102 | 0.93 | TDP1 (0.35) | TDP1ALDH1A1CA12CA1CA2 | |
| SCHEMBL7633240 | 0.91 | TDP1 (0.34) | TDP1ALDH1A1CA12CA1CA2 | |
| SCHEMBL2778608 | 0.90 | LMNA (0.36) | ALDH1A1LMNA | |
| SCHEMBL27743005 | 0.86 | LMNA (0.39) | LMNA | |
| SCHEMBL6939425 | 0.85 | LMNA (0.50) | LMNA | |
| SCHEMBL6141385 | 0.84 | — | — | |
| SCHEMBL1244548 | 0.84 | ALDH1A1 (0.42) | TDP1ALDH1A1CA12CA1CA2 | |
| SCHEMBL31086365 | 0.84 | ALDH1A1 (0.42) | TDP1ALDH1A1CA12CA1CA2 | |
| SCHEMBL7624531 | 0.83 | LMNA (0.35) | ALDH1A1LMNA | |
| SCHEMBL11966891 | 0.81 | LMNA (0.41) | TDP1ALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353555-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3377110-B1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | ABBVIE DEUTSCHLAND (DE) | 2021-01-06 | — | — | EP | disclosed |
| US-20180325833-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-15 | — | — | US | disclosed |
| EP-3377110-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-09-26 | — | — | EP | disclosed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-2474527-B1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | WAKO PURE CHEM IND LTD (JP) | 2017-01-25 | — | — | EP | disclosed |
| EP-3110810-A1 | PYRAZOLE AMIDE DERIVATIVE | Teijin Pharma Limited (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |
| CN-102482208-A | Ionic Liquid Containing Allyl Sulfonate Anion | WAKO PURE CHEM IND LTD | 2012-05-30 | — | — | CN | disclosed |
| EP-0870765-B1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARM CO LTD (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-6448247-B1 | TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) | SANKYO COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| CN-1063442-C | Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds | ZERIA PHARM CO LTD (JP) | 2001-03-21 | — | — | CN | disclosed |
| US-6159967-A | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| CN-1184471-A | Aminothiazole derivatives, drug containing the same and intermediate in the production of the compounds | ZERIA PHARM CO LTD (JP) | 1998-06-10 | — | — | CN | disclosed |
| CN-1157286-A | N,N-dimethyl-1-t-butoxycarbonyl-4-phenylpiperidine-4-carboxamide | SANKYO CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180325833-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | CLTA, ACMSD, ALKBH3 | TDP1 2445/4885ALDH1A1 366/4885CA12 701/4885 |
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | TDP1 4296/4885ALDH1A1 923/4885CA12 3754/4885 |
| US-20210353555-A1 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION | CLTA, ACMSD, ALKBH3 | TDP1 2445/4885ALDH1A1 366/4885CA12 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.